Drug Patents owned by Ferring Pharms Inc

1. Drug name - CLENPIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879 FERRING PHARMS INC Liquid pharmaceutical composition Jun, 2034

(11 years from now)

US11191753 FERRING PHARMS INC Liquid pharmaceutical composition Jun, 2034

(11 years from now)

US9827231 FERRING PHARMS INC Liquid pharmaceutical composition Jun, 2034

(11 years from now)

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
12GM/BOT;3.5GM/BOT;10MG/BOT SOLUTION;ORAL Prescription

2. Drug name - MILPROSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537584 FERRING PHARMS INC Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof Feb, 2029

(6 years from now)

US10548904 FERRING PHARMS INC Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof Feb, 2029

(6 years from now)

US8580293 FERRING PHARMS INC Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof Jan, 2030

(7 years from now)

Drugs and Companies using PROGESTERONE ingredient

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

More Information on Dosage
Strength Dosage Availability
1.78GM SYSTEM;VAGINAL Discontinued

3. Drug name - NOCDURNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307459 FERRING PHARMS INC Pharmaceutical formulations of desmopressin May, 2023

(7 months from now)

US9220747 FERRING PHARMS INC Methods using desmopressin acetate in orodispersible form May, 2023

(7 months from now)

US9919025 FERRING PHARMS INC Pharmaceutical formulations of desmopressin May, 2023

(7 months from now)

US9504647 FERRING PHARMS INC Pharmaceutical formulations of desmopressin May, 2023

(7 months from now)

US8802624 FERRING PHARMS INC Methods of treatment using orodispersible desmopressin pharmaceutical formulations Dec, 2023

(1 year, 2 months from now)

US7947654 FERRING PHARMS INC Pharmaceutical formulations Dec, 2023

(1 year, 2 months from now)

US7560429 FERRING PHARMS INC Orodispersible dosage forms of desmopressin acetate Feb, 2024

(1 year, 4 months from now)

US11020448 FERRING PHARMS INC Methods comprising desmopressin May, 2029

(6 years from now)

US10137167 FERRING PHARMS INC Methods comprising desmopressin May, 2029

(6 years from now)

US9974826 FERRING PHARMS INC Methods comprising desmopressin Apr, 2030

(7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration; Treatment of nocturia due to nocturnal polyuria in adults; treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
0.0277MG TABLET;SUBLINGUAL Prescription
0.0553MG TABLET;SUBLINGUAL Prescription

4. Drug name - PREPOPIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450338 FERRING PHARMS INC Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof Oct, 2028

(6 years from now)

US8481083 FERRING PHARMS INC Granular compositions of magnesium oxide and citric acid and uses thereof Oct, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
12GM/PACKET;3.5GM/PACKET;10MG/PACKET FOR SOLUTION;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.